Magnacent Hp

Magnacent Hp Uses, Dosage, Side Effects, Food Interaction and all others data.

Magnacent Hp contains follicle stimulating hormone (FSH) and luteinizing hormone (LH) purified from the urine of postmenopausal women. It is used as a fertility medication that is injected either subcutaneously or intramuscularly. It is composed of LH with 2 subunits, alpha = 92 residues, beta = 121 residues and FSH with 2 subunits, alpha = 92 residues, beta=111 residues.

Used to treat female infertility, Magnacent Hp stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle. Magnacent Hp bind to the LH/hCG/FSH receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge.

Magnacent Hp
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Magnacent Hp
Availability	Prescription only
Generic	Menotropins
Menotropins Other Names	Human menopausal gonadotrophin, Menotrophin, Menotropin, Menotropina, Menotropins (FSH;LH)
Related Drugs	progesterone, clomiphene, Clomid, chorionic gonadotropin (hcg), Pregnyl, Menopur, Gonal-f, Follistim, Follistim AQ
Weight	150iu
Type	Injection
Formula	C₁₀₁₄H₁₆₀₉N₂₈₇O₂₉₄S₂₇
Weight	23390.3 Da
Groups	Approved
Therapeutic Class
Manufacturer	Alkem Laboratories Ltd
Available Country	India
Last Updated:	September 19, 2023 at 7:00 am

Uses

Magnacent Hp is a purified combination of human luteinizing hormone and follicle stimulating hormone used to treat female infertility.

For the treatment of female infertility

Magnacent Hp is also used to associated treatment for these conditions: Assisted Reproductive Technology therapy

How Magnacent Hp works

Being a combination drug, Magnacent Hp bind to the follicle stimulating hormone receptor (FSH), which results in ovulation in the absence of sufficient endogenous luteinizing hormone (LH). It also binds the LH receptor, thereby stimulating proper hormone release. The drug contains both FSH and LH, therefore, it induces ovarian follicular growth and development as well as gonadal steroid production in women who do not have ovarian failure. FSH is the primary driver of follicular recruitment and growth in early folliculogenesis, while LH is important for ovarian steroidogenesis and is involved in the physiological events leading to development of a competent pre-ovulatory follicle.